BR112022013573A2 - Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre grupos - Google Patents
Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre gruposInfo
- Publication number
- BR112022013573A2 BR112022013573A2 BR112022013573A BR112022013573A BR112022013573A2 BR 112022013573 A2 BR112022013573 A2 BR 112022013573A2 BR 112022013573 A BR112022013573 A BR 112022013573A BR 112022013573 A BR112022013573 A BR 112022013573A BR 112022013573 A2 BR112022013573 A2 BR 112022013573A2
- Authority
- BR
- Brazil
- Prior art keywords
- organisms
- vaccines against
- immugens
- groups
- provide specific
- Prior art date
Links
- 244000052769 pathogen Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000005859 cell recognition Effects 0.000 abstract 1
- 238000011577 humanized mouse model Methods 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10341—Use of virus, viral particle or viral elements as a vector
- C12N2795/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
VACINAS UNIVERSAIS CONTRA IMUNÓGENOS DE ORGANISMOS PATOGÊNICOS QUE CONFEREM PROTEÇÃO ESPECÍFICA PARA ORGANISMO E ENTRE GRUPOS. A presente invenção refere-se, em parte, a uma plataforma com base em vetor de estimulação e reforço para desenvolver vacinas contra patógenos que são adaptadas para provocar uma ampla resposta de células T que têm como alvo epítopos virais conservados. As vacinas universais são preparadas contra um imunógeno de um organismo patogênico infeccioso selecionado a partir de um vírus, uma bactéria, um fungo ou um protozoário que compreende pelo menos um polinucleotídeo de ácido ribonucleico (RNA) que compreende um quadro de leitura aberta que codifica pelo menos um antígeno polipeptídico ou um fragmento imunogênico do mesmo, em que o antígeno polipeptídico, ou fragmento imunogênico do mesmo, compreende uma proteína interna conservada que é enriquecida em antígenos de reconhecimento de células T CD8(mais elevado). A eficácia da plataforma de estimulação e reforço é testada em um modelo de camundongo humanizado que compreende um sistema imune humano totalmente funcional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/105020 WO2020051766A1 (zh) | 2018-09-11 | 2018-09-11 | 一种广谱抗流感疫苗免疫原及其应用 |
US16/737,546 US11471523B2 (en) | 2018-09-11 | 2020-01-08 | Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection |
PCT/US2020/066059 WO2021141758A1 (en) | 2018-09-11 | 2020-12-18 | Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022013573A2 true BR112022013573A2 (pt) | 2022-09-13 |
Family
ID=69776980
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022013573A BR112022013573A2 (pt) | 2018-09-11 | 2020-12-18 | Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre grupos |
Country Status (7)
Country | Link |
---|---|
US (3) | US20220118077A1 (pt) |
EP (2) | EP3851120A4 (pt) |
JP (3) | JP7320601B2 (pt) |
CN (2) | CN111315407B (pt) |
AU (1) | AU2020421142A1 (pt) |
BR (1) | BR112022013573A2 (pt) |
WO (2) | WO2020051766A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY193736A (en) | 2017-11-03 | 2022-10-27 | Takeda Vaccines Inc | Method for inactivating zika virus and for determining the completeness of inactivation |
JP7443233B2 (ja) | 2017-11-30 | 2024-03-05 | タケダ ワクチン,インコーポレイテッド | ジカウイルスを不活性化する方法及び関連する方法 |
EP4031172A4 (en) * | 2019-09-16 | 2024-02-21 | Chen, Dalu | METHOD FOR BLOCKING ASV INFECTION BY DISRUPTING CELL RECEPTORS |
CN113117069B (zh) * | 2020-05-29 | 2022-09-30 | 北京启辰生生物科技有限公司 | 抗新型冠状病毒疫苗及其制备方法 |
CN113024640B (zh) * | 2020-12-28 | 2022-07-26 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 基于新冠病毒rbd与ace2受体结合结构域筛选的表位肽抗原检测中和抗体试剂盒 |
CN113171449B (zh) * | 2021-04-27 | 2022-06-07 | 青岛农业大学 | 一种甲型流感病毒通用dna疫苗及其构建方法 |
WO2022246219A2 (en) * | 2021-05-21 | 2022-11-24 | The Regents Of The University Of California | Coronavirus constructs and vaccines |
WO2023028327A1 (en) * | 2021-08-27 | 2023-03-02 | Cornell University | Multivalent viral particles |
CN113633764B (zh) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
CN114113634A (zh) * | 2022-01-24 | 2022-03-01 | 中国农业大学 | 一种检测非洲猪瘟病毒抗体的ELISA检测试剂盒以及protein L的应用 |
WO2023164475A1 (en) * | 2022-02-23 | 2023-08-31 | Akeso Therapeutics, Inc. | Modified invariant natural killer t cells expressing a chimeric antigen receptor and uses thereof |
WO2024059635A2 (en) * | 2022-09-13 | 2024-03-21 | Oregon Health And Science University | Universal t cell-based, cmv-vectored vaccine for influenza |
CN116947982B (zh) * | 2023-07-12 | 2024-05-14 | 吉林大学 | 三条优势表位肽序列及其在流感病毒疫苗的应用 |
CN117430664B (zh) * | 2023-10-24 | 2024-04-09 | 暨南大学附属第六医院(东莞市东部中心医院) | 一种甲型流感病毒t细胞抗原表位肽及其应用 |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4876197A (en) | 1983-02-22 | 1989-10-24 | Chiron Corporation | Eukaryotic regulatable transcription |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
US5135855A (en) | 1986-09-03 | 1992-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Rapid, versatile and simple system for expressing genes in eukaryotic cells |
US4844893A (en) | 1986-10-07 | 1989-07-04 | Scripps Clinic And Research Foundation | EX vivo effector cell activation for target cell killing |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
KR920007887B1 (ko) | 1989-08-29 | 1992-09-18 | 스즈키 지도오샤 고오교오 가부시키가이샤 | 내연기관의 배기가스 정화장치 |
WO1992001800A1 (en) | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
DK0671948T3 (da) | 1992-06-25 | 1997-09-01 | Smithkline Beecham Biolog | Vaccinepræparat indeholdende adjuvanser |
ES2131676T3 (es) | 1993-01-11 | 1999-08-01 | Dana Farber Cancer Inst Inc | Induccion de respuestas con linfocitos t citotoxicos. |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837484A (en) | 1993-11-09 | 1998-11-17 | Medical College Of Ohio | Stable cell lines capable of expressing the adeno-associated virus replication gene |
EP0733103B1 (en) | 1993-11-09 | 2004-03-03 | Targeted Genetics Corporation | Generation of high titers of recombinant aav vectors |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
NL9401820A (nl) | 1994-11-02 | 1996-06-03 | Meyn Maschf | Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte. |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
US6027931A (en) | 1995-08-03 | 2000-02-22 | Avigen, Inc. | High-efficiency AA V helper functions |
US5622856A (en) | 1995-08-03 | 1997-04-22 | Avigen | High efficiency helper system for AAV vector production |
EP0950091A2 (en) | 1996-12-18 | 1999-10-20 | Targeted Genetics Corporation | Aav split-packaging genes and cell lines comprising such genes for use in the production of recombinant aav vectors |
US6355257B1 (en) | 1997-05-08 | 2002-03-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
TR200002338T2 (tr) | 1998-02-12 | 2002-06-21 | Immune Complex Corporation | Stratejik olarak yenilenmiş hepatit B çekirdek proteinler. |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
IL150736A0 (en) | 2000-03-14 | 2003-02-12 | Mayr Anton | Altered strain of the modified vaccinia virus ankara (mva) |
WO2002000885A2 (en) | 2000-06-23 | 2002-01-03 | American Cyanamid Company | Assembly of wild-type and chimeric influenza virus-like particles (vlps) |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US20060024670A1 (en) * | 2004-05-18 | 2006-02-02 | Luke Catherine J | Influenza virus vaccine composition and methods of use |
EP1766034B1 (en) | 2004-05-21 | 2014-03-19 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
BRPI0609362A2 (pt) * | 2005-04-11 | 2010-03-30 | Us Gov Health & Human Serv | vetor de adenovìrus recombinante, adenovìrus recombinante, composição imunogênica e método para a produção da referida composição imunogênica |
AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
WO2007073513A2 (en) | 2005-11-10 | 2007-06-28 | Genvec, Inc. | Method for propagating adenoviral vectors encoding inhibitory gene products |
JP5198290B2 (ja) | 2006-02-02 | 2013-05-15 | グローブイミューン,インコーポレイテッド | 免疫反応を誘発する酵母ベースワクチン |
US9101578B2 (en) | 2006-05-01 | 2015-08-11 | Technovax, Inc. | Polyvalent influenza virus-like particle (VLP) compositions |
US8778353B2 (en) | 2006-05-01 | 2014-07-15 | Technovax, Inc. | Influenza virus-like particle (VLP) compositions |
AU2007300663A1 (en) * | 2006-07-21 | 2008-04-03 | Pharmexa Inc. | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions |
US9598462B2 (en) * | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
BRPI0815008B8 (pt) * | 2007-08-02 | 2021-05-25 | Biondvax Pharmaceuticals Ltd | vacinas multiméricas com múltiplos epítopos contra influenza |
CN101716340A (zh) * | 2009-10-28 | 2010-06-02 | 武汉华美生物工程有限公司 | 一种甲型h1n1流感病毒重组蛋白疫苗制备方法的建立 |
DK3205353T3 (da) * | 2011-03-21 | 2021-04-06 | Altimmune Inc | Hurtig- og langtidsvirkende immunologisk terapeutisk middel |
KR101382244B1 (ko) * | 2012-03-30 | 2014-04-08 | 재단법인 목암생명공학연구소 | 광범위한 인플루엔자 바이러스의 감염을 방어할 수 있는 t―세포 기반 유니버설 플루 백신 |
BR112015012380A2 (pt) * | 2012-12-03 | 2017-09-12 | Novartis Ag | vírus influenza recombinante |
RU2628690C2 (ru) * | 2015-11-06 | 2017-08-21 | Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' | Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний |
-
2018
- 2018-09-11 CN CN201880001963.XA patent/CN111315407B/zh active Active
- 2018-09-11 WO PCT/CN2018/105020 patent/WO2020051766A1/zh unknown
- 2018-09-11 EP EP18933057.4A patent/EP3851120A4/en active Pending
- 2018-09-11 US US17/275,253 patent/US20220118077A1/en active Pending
- 2018-09-11 JP JP2021513962A patent/JP7320601B2/ja active Active
-
2020
- 2020-01-08 US US16/737,546 patent/US11471523B2/en active Active
- 2020-12-18 EP EP20911565.8A patent/EP4087603A4/en active Pending
- 2020-12-18 BR BR112022013573A patent/BR112022013573A2/pt not_active Application Discontinuation
- 2020-12-18 AU AU2020421142A patent/AU2020421142A1/en active Pending
- 2020-12-18 JP JP2022542402A patent/JP2023510542A/ja active Pending
- 2020-12-18 CN CN202080098295.4A patent/CN116096403A/zh active Pending
- 2020-12-18 WO PCT/US2020/066059 patent/WO2021141758A1/en unknown
-
2022
- 2022-06-10 US US17/837,861 patent/US20220347287A1/en not_active Abandoned
-
2023
- 2023-04-05 JP JP2023061353A patent/JP2023093541A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2020051766A1 (zh) | 2020-03-19 |
US20220118077A1 (en) | 2022-04-21 |
US11471523B2 (en) | 2022-10-18 |
EP3851120A1 (en) | 2021-07-21 |
EP4087603A1 (en) | 2022-11-16 |
JP7320601B2 (ja) | 2023-08-03 |
US20220347287A1 (en) | 2022-11-03 |
CN111315407B (zh) | 2023-05-02 |
WO2021141758A1 (en) | 2021-07-15 |
US20210100892A1 (en) | 2021-04-08 |
AU2020421142A1 (en) | 2022-08-18 |
JP2022513558A (ja) | 2022-02-09 |
EP3851120A4 (en) | 2022-04-27 |
CN111315407A (zh) | 2020-06-19 |
JP2023510542A (ja) | 2023-03-14 |
CN116096403A (zh) | 2023-05-09 |
EP4087603A4 (en) | 2024-01-10 |
JP2023093541A (ja) | 2023-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022013573A2 (pt) | Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre grupos | |
Mohn et al. | Immune responses after live attenuated influenza vaccination | |
Raeven et al. | Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination | |
MX2021010519A (es) | Proteinas f de rsv de prefusion y su uso. | |
Cardoso et al. | Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen | |
EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
Qureshi et al. | Estimation of titers of antibody against Pasteurella multocida in cattle vaccinated with haemorrhagic septicemia alum precipitated vaccine | |
RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
CN109701010A (zh) | 疫苗复合佐剂系统及其在抗原中的应用 | |
WO2022165340A3 (en) | Universal vaccines against immunogens of pathogenic organisms that provide organism-specific and cross-group protection | |
Cauchemez et al. | Education and mental health: good reasons to vaccinate children | |
CN105143251A (zh) | 流感核蛋白疫苗 | |
Trotta et al. | Simultaneous immunization of cattle with foot-and-mouth disease (FMD) and live anthrax vaccines do not interfere with FMD booster responses | |
CN102266551B (zh) | 可用于治疗人或动物免疫相关性疾病的白介素-4治疗性疫苗 | |
CN103110943B (zh) | 一种可替代氢氧化铝的新型疫苗佐剂 | |
Kashino et al. | Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates | |
Lin et al. | Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant | |
Kapustin et al. | The results of clinical studies of safety, antigenic activity and effectiveness of inactivated vaccine" VERRES-KOLIKLOST" against escherichiosis and clostridiosis of pigs | |
CN105950646A (zh) | 一种以芽孢型益生菌为粘膜递送载体的禽流感通用疫苗的构建方法及应用 | |
BR112022011422A2 (pt) | Imunógenos para vírus da caxumba e do sarampo e seus usos | |
Geeraedts et al. | Influenza vaccines: what do we want and how can we get it? | |
CN103948942B (zh) | 一种流感病毒通用疫苗及其制备方法 | |
Feng et al. | Food Additives as Novel Influenza Vaccine Adjuvants | |
Han et al. | Immunogenicity and safety of the new reduced-dose tetanus–diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study | |
World Health Organization | Immunological basis for immunization: module 2: diphtheria-update 2009 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |